trimetrexate has been researched along with Lung Neoplasms in 16 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Echinomycin is a potent bifunctional intercalator of double-strand DNA; trimetrexate is a new derivative of methotrexate and is active against methotrexate-resistant tumor cells in vitro." | 2.69 | A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). ( Blum, RH; Bonomi, P; Boucher, H; Chang, AY; Karp, DD; Kim, K; Stewart, JA, 1998) |
| "Trimetrexate (150 mg/m2) was administered intravenously over 30 minutes every 2 weeks." | 2.67 | A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group. ( Ebbert, LP; Foley, JF; Gesme, DH; Hatfield, AK; Jett, JR; Krook, JE; Mailliard, JA; Maksymiuk, AW; Schreffler, DD; Su, JQ, 1993) |
| " The dosage schedule was single-dose intravenous administration (single treatment), followed by one or two courses of 5-day intravenous administration (5-day treatment) at 3-week intervals." | 2.67 | [Phase I study of CI-898. CI-898 Study Group]. ( Ariyoshi, H; Furue, H; Hasegawa, K; Majima, H; Nakao, I; Niitani, H; Ohta, K; Taguchi, T; Tsukagoshi, S; Yasutomi, M, 1991) |
| "Trimetrexate is a nonclassical antifolate with greater preclinical antitumor activity than methotrexate." | 1.28 | Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer. ( Burke, MT; D'Acquisto, RW; Fanucchi, MP; Gralla, RJ; Heelan, RT; Kris, MG; Marks, LD, 1989) |
| "Trimetrexate glucuronate was evaluated in 70 nonsmall cell lung cancer patients with incurable disease and/or demonstrated progression following surgery/radiotherapy and no prior cytotoxic chemotherapy." | 1.27 | Clinical response to trimetrexate as sole therapy for nonsmall cell lung cancer. ( Maroun, J, 1988) |
| " The dosage chosen for the Phase 2 study, based only on the hematological dose limiting toxicity, was 10." | 1.27 | Trimetrexate and cyclophosphamide for metastatic inoperable nonsmall cell lung cancer. ( Grove, W; Holsti, LR; Maasilta, P; Mattson, K; Tammilehto, L, 1988) |
| "Trimetrexate was administered intravenously together with 20 mg/m2 cisplatin or 50 mg/m2 etoposide for 5 consecutive days at an initial dose of 4 mg/m2." | 1.27 | Trimetrexate combined with cisplatin or etoposide in the treatment of non-small cell lung cancer: a pilot study. ( Maroun, JA; Natale, RB; Robert, F, 1988) |
| "Thrombocytopenia was dose limiting, but highly variable among patients at a given dose level; other toxicity was mild and uncommon." | 1.27 | Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. ( Cassidy, C; Chou, TC; Fanucchi, MP; Fleisher, M; Lokos, G; Niedzwiecki, D; Vidal, P; Walsh, TD; Williams, L; Young, CW, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (31.25) | 18.7374 |
| 1990's | 11 (68.75) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kuyper, LF | 1 |
| Baccanari, DP | 1 |
| Jones, ML | 1 |
| Hunter, RN | 1 |
| Tansik, RL | 1 |
| Joyner, SS | 1 |
| Boytos, CM | 1 |
| Rudolph, SK | 1 |
| Knick, V | 1 |
| Wilson, HR | 1 |
| Caddell, JM | 1 |
| Friedman, HS | 1 |
| Comley, JC | 1 |
| Stables, JN | 1 |
| Gesme, DH | 1 |
| Jett, JR | 1 |
| Schreffler, DD | 1 |
| Su, JQ | 1 |
| Mailliard, JA | 1 |
| Foley, JF | 1 |
| Krook, JE | 1 |
| Maksymiuk, AW | 1 |
| Hatfield, AK | 1 |
| Ebbert, LP | 1 |
| Haller, DG | 1 |
| Chang, AY | 1 |
| Kim, K | 1 |
| Boucher, H | 1 |
| Bonomi, P | 1 |
| Stewart, JA | 1 |
| Karp, DD | 1 |
| Blum, RH | 1 |
| Robson, C | 1 |
| Wright, KA | 1 |
| Twentyman, PR | 1 |
| Lambert, PA | 1 |
| Griffin, RJ | 1 |
| Faessel, HM | 1 |
| Slocum, HK | 1 |
| Rustum, YM | 1 |
| Greco, WR | 1 |
| Fossella, FV | 1 |
| Winn, RJ | 1 |
| Holoye, PY | 1 |
| Hallinan, B | 1 |
| Raber, MN | 1 |
| Hoelzer, K | 1 |
| Young, JA | 1 |
| Readling, J | 1 |
| Bowers, B | 1 |
| Hong, WK | 1 |
| Yoshimura, A | 1 |
| Taguchi, T | 1 |
| Tsukagoshi, S | 1 |
| Furue, H | 1 |
| Niitani, H | 1 |
| Ohta, K | 1 |
| Ariyoshi, H | 1 |
| Hasegawa, K | 1 |
| Majima, H | 1 |
| Nakao, I | 1 |
| Yasutomi, M | 1 |
| Mattson, K | 2 |
| Kinnula, V | 1 |
| Maasilta, P | 2 |
| Kajanti, M | 1 |
| Niiranen, A | 1 |
| Maasilta, PK | 1 |
| Rautonen, JK | 1 |
| Mattson, MT | 1 |
| Mattson, KV | 1 |
| Kris, MG | 1 |
| D'Acquisto, RW | 1 |
| Gralla, RJ | 1 |
| Burke, MT | 1 |
| Marks, LD | 1 |
| Fanucchi, MP | 2 |
| Heelan, RT | 1 |
| Maroun, J | 1 |
| Tammilehto, L | 1 |
| Holsti, LR | 1 |
| Grove, W | 1 |
| Maroun, JA | 1 |
| Natale, RB | 1 |
| Robert, F | 1 |
| Walsh, TD | 1 |
| Fleisher, M | 1 |
| Lokos, G | 1 |
| Williams, L | 1 |
| Cassidy, C | 1 |
| Vidal, P | 1 |
| Chou, TC | 1 |
| Niedzwiecki, D | 1 |
| Young, CW | 1 |
2 reviews available for trimetrexate and Lung Neoplasms
| Article | Year |
|---|---|
Trimetrexate: experience with solid tumors.
Topics: Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Clinical Trials a | 1997 |
[New analogues of methotrexate].
Topics: Aminopterin; Animals; Antineoplastic Agents; Drug Administration Schedule; Female; Humans; Lung Neop | 1992 |
4 trials available for trimetrexate and Lung Neoplasms
| Article | Year |
|---|---|
A randomized phase II trial of amonafide or trimetrexate in patients with advanced non-small cell lung cancer. A trial of the North Central Cancer Treatment Group.
Topics: Adenine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Drug | 1993 |
A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587).
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antine | 1998 |
Phase II trial of trimetrexate for unresectable or metastatic non-small cell bronchogenic carcinoma.
Topics: Adult; Aged; Carcinoma, Bronchogenic; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; | 1992 |
[Phase I study of CI-898. CI-898 Study Group].
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Digestive System Neoplasms; Drug Administratio | 1991 |
10 other studies available for trimetrexate and Lung Neoplasms
| Article | Year |
|---|---|
High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size.
Topics: Animals; Anti-Infective Agents; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B | 1996 |
Chemical synthesis and biological properties of novel fluorescent antifolates in Pgp- and MRP-overexpressing tumour cell lines.
Topics: 4-Chloro-7-nitrobenzofurazan; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, | 1998 |
Folic acid-enhanced synergy for the combination of trimetrexate plus the glycinamide ribonucleotide formyltransferase inhibitor 4-[2-(2-amino-4-oxo-4,6,7,8-tetrahydro-3H-pyrimidino[5,4,6][1,4]thiazin -6-yl)-(S)-ethyl]-2,5-thienoylamino-L-glutamic acid (AG
Topics: Adenocarcinoma; Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Division; Colonic Neoplasms; D | 1999 |
Phase II study of trimetrexate and cyclophosphamide in previously untreated patients with inoperable non-small cell lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small | 1990 |
Quality of life assessment during chemotherapy for non-small cell lung cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cyclophosphamide; Dr | 1990 |
Phase II trial of trimetrexate in patients with stage III and IV non-small-cell lung cancer.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Drug Administration Schedule; Drug Evaluation; Female; | 1989 |
Clinical response to trimetrexate as sole therapy for nonsmall cell lung cancer.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Female; Humans; Lung | 1988 |
Trimetrexate and cyclophosphamide for metastatic inoperable nonsmall cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cycloph | 1988 |
Trimetrexate combined with cisplatin or etoposide in the treatment of non-small cell lung cancer: a pilot study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Carcinoma, Non-Small-Cell | 1988 |
Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks.
Topics: Adenocarcinoma; Adult; Aged; Bone Marrow; Chromatography, High Pressure Liquid; Deoxyuridine; Drug E | 1987 |